AbbVie Reports Positive Results for Skin Disease Drug
A late-stage trial shows lutikizumab reduces inflammatory lesions in patients with hidradenitis suppurativa.
Updated on Oct. 22, 2026 in Weight Loss
Live Poll
Do you trust pharmaceutical companies to prioritize affordable innovation when developing new treatments for chronic conditions?
AbbVie announced that its drug lutikizumab met primary goals in a clinical trial for hidradenitis suppurativa. Patients receiving the treatment saw a reduction in inflammatory skin lesions over a 16-week period.
Why it matters
The company aims to address the significant disease burden of hidradenitis suppurativa, a condition worsened by obesity. This effort includes future plans to study combination treatments with its weight-loss drug pipeline.
In a study of 1,400 patients, 31% of those treated with lutikizumab saw at least a 75% reduction in inflammatory lesions after 16 weeks, compared to 23% in the placebo group.
The players
AbbVie
This global biopharmaceutical company focuses on developing advanced therapies for complex and severe diseases.
Gubra
This Danish biotech company specializes in the discovery and development of peptide-based treatments for metabolic and inflammatory diseases.
The details
The trial measured the reduction of inflammatory lumps and abscesses in participants living with the chronic skin condition. AbbVie previously licensed the amylin-mimicking weight-loss drug ABBV-295 from the Danish biotech firm Gubra in 2025.
Timeline
In 2025, AbbVie licensed the weight-loss drug ABBV-295 from Gubra.
On October 22, 2026, AbbVie reported the late-stage study results.
By the end of 2026, the company expects to begin testing the combination of lutikizumab and ABBV-295.
By the end of 2026, Rinvoq late-stage trial results for hidradenitis suppurativa are expected.
The total market for hidradenitis suppurativa treatments is projected to exceed $10 billion by 2035.
Health Landscape
This clinical success marks a competitive advancement in the growing hidradenitis suppurativa treatment market. It highlights a shift toward addressing comorbid conditions, such as obesity, to improve outcomes for patients with chronic inflammatory diseases.
Patients suffering from hidradenitis suppurativa may eventually gain access to more targeted treatment options that address both inflammatory symptoms and associated weight challenges. These developments could eventually provide doctors with new combination therapies to better manage the disease.
The takeaway
Advancements in dual-therapy research suggest a growing focus on the relationship between metabolic health and autoimmune disease management. Patients and providers should monitor future trial outcomes for potential shifts in long-term treatment protocols.
What happens next
AbbVie plans to initiate combination therapy testing for lutikizumab and ABBV-295 by the end of 2026. Additionally, the company is scheduled to release late-stage trial results for the drug Rinvoq in treating hidradenitis suppurativa by the end of 2026.
Further reading
Learn more about the latest innovations in metabolic health and chronic disease management at the Weight Loss section.
Live Poll
Do you trust pharmaceutical companies to prioritize affordable innovation when developing new treatments for chronic conditions?
